KCM
KRYS icon

Kennedy Capital Management’s Krystal Biotech KRYS Stock Holding History

Kennedy Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
4,904
+403
+9% +$107K 0.03% 462
2025
Q4 		$1.11M Sell
4,501
-34,790
-89% -$7.32M 0.02% 476
2025
Q3 		$6.94M Buy
39,291
+1,145
+3% +$171K 0.15% 233
2025
Q2 		$5.24M Sell
38,146
-3,372
-8% -$495K 0.13% 283
2025
Q1 		$7.49M Buy
41,518
+13,807
+50% +$2.32M 0.18% 198
2024
Q4 		$4.34M Buy
27,711
+22,517
+434% +$3.99M 0.1% 351
2024
Q3 		$945K Buy
5,194
+237
+5% +$45.7K 0.02% 595
2024
Q2 		$910K Buy
4,957
+2,056
+71% +$345K 0.02% 599
2024
Q1 		$516K Sell
2,901
-26,772
-90% -$3.72M 0.01% 656
2023
Q4 		$3.68M Buy
+29,673
New +$3.29M 0.08% 365
2023
Q2 		– Sell
-25,807
Closed -$2.07M – 681
2023
Q1 		$2.07M Sell
25,807
-13
-0.1% -$1.02K 0.06% 396
2022
Q4 		$2.05M Sell
25,820
-1,465
-5% -$109K 0.06% 411
2022
Q3 		$1.9M Buy
+27,285
New +$1.97M 0.06% 423

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's KRYS Position: Q1 2026 in Review

Kennedy Capital Management increased its Krystal Biotech (KRYS) stake by 9% in Q1 2026, buying an estimated $107K and bringing the position to 4,904 shares worth $1.27M. The position accounts for 0.03% of the portfolio, ranked #462.

Kennedy Capital Management first reported a position in KRYS in Q3 2022 and has held it in 13 quarters since. The position peaked at $7.49M in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Kennedy Capital Management held 4,904 shares of Krystal Biotech worth $1.27M as of Q1 2026.
  • Kennedy Capital Management bought 403 Krystal Biotech shares in Q1 2026, an estimated $107K.
  • Krystal Biotech made up 0.03% of Kennedy Capital Management's portfolio in Q1 2026, its #462 holding.
  • Kennedy Capital Management first reported a position in Krystal Biotech in Q3 2022 and has held it in 13 quarters since.
  • Kennedy Capital Management's Krystal Biotech position peaked at $7.49M in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.